Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)

Filter results: >>>>
Cell Clinical Subtype Transcriptional Subtype Small Molecule Antibody Perturbagen Target Perturbagen Class Biological Replicate ID Conc Unit GR50 GEC50 GRmax GRinf GR Hill Coefficient GR_AOC GR r2 Nominal Division Rate
MCF12A
NM
Basal B
PS-1145
IKK
NFKB
7490.065
uM
inf
inf
0.9204 0.9204 0.0000 -0.0153
0.3912
2.4816
HCC1187
TNBC
Basal A
AG1024
IGF1R
RTK
7433.066
uM
49.0820
39.44790
0.7887 0.3207 4.6933 -0.0151
0.7750
1.0755
BT-549
TNBC
Basal B
Sorafenib
PDGFR/VEGFR/KIT/FLT3
RTK
5909.085
uM
inf
inf
0.8983 0.8983 0.0000 -0.0146
-0.0760
3.0853
HCC38
TNBC
Basal B
Cetuximab
EGFR
ErbB
10268.122
uM
0.92849
0.80222
0.7620 0.2528 4.8199 -0.0144
0.6866
0.6345
SUM159PT
TNBC
Basal B
Nilotinib
ABL
nRTK
11057.145
uM
inf
inf
1.0062 1.0062 0.0000 -0.0143
-0.1841
3.8266
HCC3153
TNBC
Basal A
L-779450
BRAF
MAPK
10937.149
uM
45.2220
35.9980
0.7333 0.3402 4.9999 -0.0142
0.8321
1.3519
184A1
NM
Basal
GM6001
MMP
MMP
5895.096
uM
inf
inf
0.9763 0.9763 0.0000 -0.0141
-0.1057
1.4232
MCF7
HR+
Luminal
Selumetinib
MEK
MAPK
10997.155
uM
inf
inf
0.9524 0.9524 0.0000 -0.0139
0.0569
1.3159
MDA-MB-157
TNBC
Basal B
Erlotinib
EGFR
ErbB
7498.091
uM
inf
27.1530
0.7131 0.7029 3.6973 -0.0137
0.8545
1.1445
HCC38
TNBC
Basal B
Erlotinib
EGFR
ErbB
7469.09
uM
inf
79.23380
0.8694 0.5898 4.4214 -0.0137
0.6395
1.9867
MCF12A
NM
Basal B
FTase Inhibitor I
Ftase
MAPK
12365.167
uM
inf
inf
1.0500 1.0500 0.0000 -0.0137
-0.2379
2.0273
HCC1143
TNBC
Basal A
Lapatinib
EGFR/HER2
ErbB
7430.098
uM
inf
inf
0.9114 0.9114 0.0000 -0.0137
0.0580
1.9267
HCC38
TNBC
Basal B
GW843682X
PLK
PLK
10578.139
uM
inf
inf
0.9988 0.9988 0.0000 -0.0137
-0.1933
1.6434
MCF7
HR+
Luminal
Cetuximab
EGFR
ErbB
7875.018
uM
inf
inf
0.9316 0.9316 0.0000 -0.0136
0.3967
1.6565
MDA-MB-361
HER2amp
Luminal
SB-3CT
MMP2/9
MMP
10999.144
uM
inf
33.74850
0.8575 0.8559 4.1065 -0.0135
0.6799
0.6880
Hs 578T
TNBC
Basal B
Lapatinib
EGFR/HER2
ErbB
7475.098
uM
inf
inf
1.0092 1.0092 0.0000 -0.0133
-0.1678
2.2876
MDA-MB-134-VI
HR+
Luminal
Trastuzumab
HER2
ErbB
10077.026
uM
7.0350
7.93710
0.4622 -0.4084 4.9480 -0.0133
0.9348
0.3999
Hs 578T
TNBC
Basal B
CPT-11
TOP1
TOP
7863.007
uM
inf
52.97460
0.7011 0.5937 3.0757 -0.0133
0.8737
1.4578
SK-BR-3
HER2amp
Luminal
Trametinib
MEK
MAPK
9759.012
uM
inf
inf
0.9728 0.9728 0.0000 -0.0132
-0.0794
1.3591
MDA-MB-415
HR+
Luminal
PD184352
MEK
MAPK
10938.155
uM
inf
inf
1.0500 1.0500 0.0000 -0.0131
-0.0082
0.5336
CAMA-1
HR+
Luminal
L-779450
BRAF
MAPK
10473.137
uM
inf
inf
0.8531 0.8531 0.0000 -0.0131
0.5134
1.1322
MDA-MB-415
HR+
Luminal
PD184352
MEK
MAPK
10938.155
uM
inf
inf
1.0500 1.0500 0.0000 -0.0131
-0.0082
0.5336
BT-483
HR+
Luminal
Gefitinib
EGFR
ErbB
9186.049
uM
36.87510
34.94230
0.6087 0.1151 4.8579 -0.0129
0.8969
0.6923
SUM1315MO2
TNBC
Basal B
PS-1145
IKK
NFKB
9044.065
uM
inf
inf
0.8636 0.8636 0.0000 -0.0127
0.3821
0.5944
MB 157
Unknown
Unknown
FTase Inhibitor I
Ftase
MAPK
12580.167
uM
inf
inf
1.0233 1.0233 0.0000 -0.0124
-0.4459
2.1970